I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

I-123-MIBG for Imaging of Neuroblastoma and Pheochromocytoma

I-123-MIBG is used to image patients with neuroblastoma, pheochromocytoma and other neural crest tumors

Entry criteria--Histologically documented neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma.

Exclusion criteria--Pregnancy Randomization--None Procedure--Patients will receive a dose of I-123-MIBG by intravenous injection. Images will obtained at 18-24 hours after administration of the drug and at 42-48 hours as needed. SSKI will be used to block thyroid uptake of free I-123-iodide

Inclusion Criteria:

• Histologically proven neuroblastoma or pheochromocytoma or strong suspicion of neuroblastoma or pheochromocytoma

Exclusion Criteria:

• Pregnancy